[A19-78] Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Project no.:
A19-78
Commission:
Commission awarded on 02.09.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with Waldenström macroglobulinaemia
Result of dossier assessment:
Added benefit not proven due to lack of suitable study data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.